Why Virbac (ENXTPA:VIRP) is on investors’ radar today Virbac (ENXTPA:VIRP) is drawing attention after its recent share performance and latest reported financial figures, prompting investors to reassess how this €3.1b animal health company fits into their portfolios. See our latest analysis for Virbac. Virbac’s share price has eased in the last week, with a 1 day share price return decline of 2.42% and a 7 day share price return decline of 2.81%. However, the 1 year total shareholder return of...

Investing.com -- Shares of Virbac SA (EPA:VIRB) jumped more than 2% on Friday after the company reported first-quarter revenue of €384 million, up 7.7% at constant exchange rates and scope, driven by a 20.7% surge in North America that more than offset currency headwinds and competitive pressure in the Pacific.

Why Virbac stock is on investors’ radar Virbac (ENXTPA:VIRP) has drawn fresh attention after recent price moves, with the share closing at €353. Investors are weighing this level against its recent returns and current earnings profile. See our latest analysis for Virbac. The recent 5.53% one day share price return and 4.13% 7 day share price return come against a flatter year to date move, while the 1 year total shareholder return of 13.83% points to momentum that has built more gradually...

If you are wondering whether Virbac at €361.50 is offering fair value or an opportunity, the key is to understand what the current share price actually reflects. The stock has recorded returns of 1.7% over 7 days, 6.6% over 30 days, 2.3% year to date, 16.0% over 1 year, 42.2% over 3 years and 76.3% over 5 years. This history shapes how the market is currently pricing expectations and risks. These moves sit against a backdrop of ongoing interest in the animal health sector and Virbac's...

Virbac's stock has recently seen a subtle, yet notable, change in its fair value estimate, increasing from €397.61 to €403.20. This revision comes as optimism grows over the company's operational momentum and geographic expansion. The discount rate has also edged up from 5.98% to 6.18%. Stay tuned to discover how investors and analysts are tracking these narrative shifts and how you can keep informed on further updates. Stay updated as the Fair Value for Virbac shifts by adding it to your...

Thinking about what to do with your GL Events shares? Whether you are sizing up an entry point or reassessing your position after a strong rally, now is a great time to take stock of what is really happening beneath the surface. GL Events is one of those names where, if you had blinked a year ago, you might have missed some serious upside. Over the past five years, the stock has delivered a remarkable 219.9% return, and it is up 103.9% over three years alone. Even with a recent pullback of...

If you are eyeing Virbac and weighing your next move, you are not alone. The French animal health specialist has been on a bit of a rollercoaster recently, making investors sit up and reconsider its long-term prospects. Over the last five years, the stock has soared an impressive 80.1%. That kind of gain catches attention, even if the recent numbers suggest a more complex picture. Year-to-date, Virbac is up almost 2%, but there's been a slight dip over the past month and week, down 2% and...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.